Some startups chase trends. Others build the kind of tech that makes entire industries rethink their rhythm. Weave Bio belongs in the second category. Founded in 2022 by Brandon Rice, this San Francisco startup isn’t just adding AI to life sciences, it’s building an AI-native nervous system for regulatory automation. The company just closed a $20M Series A led by USVP, with support from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. That’s not just capital, it’s conviction from some of the sharpest minds in venture that compliance and innovation can finally move at the same speed.
Weave Bio’s mission is deceptively simple: turn the nightmare of regulatory submissions into a precise, automated workflow that actually works. Their cloud-based platform infuses AI into every stage of the therapeutic lifecycle, from data extraction and dossier authoring to eCTD submission and health-authority query management. In an industry where “manual” still dominates multi-billion-dollar processes, their model has delivered over 50% faster timelines for clients and a 97% time savings in IND summary prep for Takeda. That’s not automation for automation’s sake, it’s an execution advantage.
Brandon Rice built Weave Bio to crush the lag between discovery and approval. And he’s not doing it alone. With Maria Nguyen as COO, Dr. Samuel Ortiz as Head of Regulatory Affairs, and Allison Becker leading Product, this team brings experience from FDA, Genentech, Pfizer, and Oracle Health Sciences. They’ve built a product that doesn’t just predict, it performs, threading AI through every document, data point, and decision. Their “six clicks to submission” mantra feels less like marketing and more like a quiet revolution.
The Series A unlocks a new chapter. Funds will scale the platform to cover NDA/BLA and post-market submissions, build deeper integrations with clinical and safety systems, and expand global reach across Europe, Japan, and LATAM by 2026. It’s a calculated sprint backed by infrastructure as disciplined as their design: containerized microservices, adaptive AI templates, real-time compliance checks, and SOC2 Type II rigor.
What makes this story hit harder than a headline is the inevitability behind it. Regulation has always been the drag coefficient on innovation. Weave Bio is turning that drag into drive, an AI engine that powers the future of compliant drug development. The next era of life sciences won’t be handwritten. It’ll be Weaved.
